Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with ω-3 or ω-6 fatty acids and corticosteroids

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 10, 2005, Pages 1214-1221

  Eivindson, Martin ^a,b   Grønbæk, Henning ^b   Nielsen, Jens Nederby ^a   Frystyk, Jan ^b   Flyvbjerg, Allan ^b   Jørgensen, Lone ^a   Vind, Ida ^c   Munkholm, Pia ^c   Jensen, Søren ^d   Brandslund, Ivan ^a,e   Hey, Henrik ^a,e  

^a LILLEBAELT HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d KOLDING HOSPITAL   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

3 6 fatty acids; CDAI score; Crohn's disease; IGF I; IGFBP 1; IGFBP 3; IGFBP 3 protease; Inflammatory bowel disease; Nutrition

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PREDNISOLONE; PROTEINASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADJUVANT THERAPY; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENTERIC FEEDING; ENZYME ACTIVITY; FEMALE; GROWTH DISORDER; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CROHN DISEASE; ENDOPEPTIDASES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; IMMUNOASSAY; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MIDDLE AGED; PREDNISOLONE; SOMATOMEDINS; TREATMENT OUTCOME;

EID: 27144527515     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520510015728     Document Type: Article

References (40)

1. Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995;3:38-61.
2. Frystyk J, Skjaerbæk C, Dinesen B, Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEES Lett 1994;348:185-91.
3. Tenore A, Berman WF, Parks JS, Bongiovanni AM. Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease. J Clin Endocrinol Metab 1977;44:622-8.
4. Braegger CP, Torresani T, Murch SH, Savage MO, Walker-Smith JA, MacDonald TT. Urinary growth hormone in growth-impaired children with chronic inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16:49-52.
5. Farthing MJ, Campbell CA, Walker-Smith J, Edwards CR, Rees LH, Dawson AM. Nocturnal growth hormone and gonadotrophin secretion in growth retarded children with Crohn's disease. Gut 1981;22:933-8.
6. Grønbæk H, Thøgersen T, Frystyk J, Vilstrup H, Flyvbjerg A, Dahlerup JF. Low free and total insulin-like growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. Am J Gastroenterol 2002;97:673-8.
7. Beattie RM, Camacho-Hübner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, Savage MO. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol (Oxf) 1998;49:483-9.
8. Corkins MR, Gohil AD, Fitzgerald JF. The insulin-like growth factor axis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003;36:228-34.
9. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 2001;11:364-7.
10. Bannerjee K, Camacho-Hübner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004;38:270-5.
11. Stoving RK, Hangaard J, Hagen C, Flyvbjerg A. Low levels of the 150-kD insulin-like growth factor binding protein 3 ternary complex in patients with anorexia nervosa: effect of partial weight recovery. Horm Res 2003;60:43-8.
12. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80-101.
13. Underwood LE. Nutritional regulation of IGF-I and IGFBPs. J Pediatr Endocrinol Metab 1996;9(Suppl 3):303-12.
14. Nørrelund H, Frystyk J, Jørgensen JO, Møller N, Christiansen JS, Ørskov H, et al. The effect of growth hormone on the insulin-like growth factor system during fasting. J Clin Endocrinol Metab 2003;88:3292-8.
15. O'Morain C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br Med J 1984;288:1859-62.
16. Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease? Scand J Gastroenterol 2001;36:383-8.
17. Fernández-Bañares F, Cabré E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enterai Nutr 1995;19:356-64.
18. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056-67.
19. Messori A, Trallori G, D'Albasio G, Milla M, Vannozzi G, Pacini F. Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Scand J Gastroenterol 1996;31:267-72.
20. Gassull MA, Fernández-Bañares F, Cabré E, Papo M, Giaffer MH, Sánchez-Lombraña JL, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double-blind randomised multicentre European trial. Gut 2002;51:164-8.
21. Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Löschke K. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease: a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med 1989;225(Suppl 731):225-32.
22. Frystyk J, Dinesen B, Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Reg 1995;5:169-76.
23. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW, et al. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003;88:132-5.
24. Westwood M, Gibson JM, Davies AJ, Young RJ, White A. The phosphorylation pattern of insulin-like growth factor-binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. J Clin Endocrinol Metab 1994;79:1735-41.
25. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 1986;154:138-43.
26. Flyvbjerg A, Kessler U, Dorka B, Funk B, Ørskov H, Kiess W. Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 1992;35:589-93.
27. Lamson G, Giudice LC, Rosenfeld RG. A simple assay for proteolysis of IGFBP-3. J Clin Endocrinol Metab 1991;72:1391-3.
28. Wolf M, Bohm S, Brand M, Kreymann G. Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996;135:729-37.
29. Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 2002;58(Suppl 1):7-10.
30. De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001;142:4818-26.
31. Thomas AG, Holly JM, Taylor F, Miller V. Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut 1993;34:944-7.
32. Akobeng AI, Clayton PE, Miller V, Hall CM, Thomas AG. Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease: effect of enteral nutritional support and glutamine supplementation. Scand J Gastroenterol 2002;37:1422-7.
33. Skjærbæk C, Frystyk J, Ørskov H, Kissmeyer-Nielsen P, Jensen MB, Laurberg S, et al. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab 1998;83:2445-9.
34. Cwyfan Hughes SC, Cotterill AM, Molloy AR, Cassell TB, Braude N, Hinds CJ, et al. The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery. J Endocrinol 1992;135:135-45.
35. Davenport ML, Isley WL, Pucilowska JB, Pemberton LB, Lyman B, Underwood LE, et al. Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab 1992;75:590-5.
36. Davies SC, Wass JA, Ross RJ, Cotterill AM, Buchanan CR, Coulson VJ, et al. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 1991;130:469-73.
37. Street ME, de'Angelis G, Camacho-Hübner C, Giovannelli G, Ziveri MA, Bacchini PL, et al. Relationships between serum IGF-I, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res 2004;61:159-64.
38. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643-50.
39. Fernández-Bañares F, Cabré E, González-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn's disease. Gut 1994;35(Suppl 1):S55-S9.
40. Cabré E, Gassull MA. Nutritional and metabolic issues in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2003;6:569-76.